Pharmaceutical efficacy of harmalol in inhibiting hepatocellular carcinoma

Sarita Sarkar, Paromita Bhattacharjee, Tapas Ghosh and Kakali Bhadra

Abstract

Background: Diethylnitrosamine (DEN) promoted by carbon tetrachloride (CCl₄) forms DNA adducts inducing hepatocellular carcinoma (HCC). Plant alkaloid, harmalol, is being used as a therapeutic agent against HCC due to its accessibility and efficacy by apoptosis and inhibiting proliferation of cancer epithelial cells.

Result: Seven groups of Swiss albino mice were taken. Different stages of liver tissues and serum from various experimental groups were collected before and after harmalol treatment. The investigation was carried out by enzyme assay, bilirubin level in the blood, DNA, RNA, normal serum protein of liver tissue, and alpha-feto protein estimation of serum. Gross morphological assessment of liver, histological, and different apoptosis markers viz. p53, caspase3, and cytochrome C expression were analyzed by RT-PCR and Western blot. Harmalol (10 mg/kg B.W. per week, I.P.) for 9 weeks showed a significant reduction in hepatocellular foci, nodules, and carcinoma ultimately retaining the normal morphology. It further induces ROS-dependent apoptosis through mitochondrial cytochrome C release that induces p53 by caspase3 activation.

Conclusion: The investigation will eventually help to develop more effective chemotherapeutic drugs from the natural source.

Keywords: Harmalol, Histology, DEN, CCl₄, HCC, Apoptosis, ROS, Caspase3, p53

Background

The liver is a key metabolic organ that is essential for the production of blood proteins, lipid and sugar metabolism, and detoxification of naturally occurring and foreign harmful chemicals. In Asia and Africa, hepatocarcinogenesis is one of the major causes of cancer deaths [1]. To maintain its mass and many essential functions, the liver possesses a remarkable regenerative capacity, but the latter also renders it highly susceptible to carcinogenesis. In fact, liver cancer often develops in the context of chronic liver injury [2]. The most common form of primary liver cancer, hepatocellular carcinoma (HCC), involves multistep processes which are correlated with different genetic alterations that ultimately lead to malignant transformation of the hepatocytes [3]. Among several liver cancer-inducing agents, diethylnitrosamine (DEN) (Fig. 1a, inset) often induces malignant tumors in the target organ and is species-specific. DEN has been reported to cause the generation of ROS, forming DNA-carcinogen adducts in the liver and resulting in oxidative stress and cellular injury [4]. This potent genotoxic compound is widely found in the environment and present in tobacco smoke, varieties of food such as cheese, salted and dried fish, soybean, cured meat, alcoholic beverages, cosmetics, agricultural chemicals, several pharmaceutical agents, and ground water having a high level of nitrates making the human population vulnerable to its exposure and is also synthesized endogenously [5, 6]. As preservatives, nitrates and nitrite salts are used in numerous foodstuffs in the food industry since 1920 to preserve the natural color of meat and the typical taste of processed, smoked, and cured meat and meat products. Meat proteins especially amines can react with the nitrates and produce N-nitrosamines [7]. As nitrosamine is found in food preservatives as an environmental
dietary carcinogen, an intensive study has been conducted on DEN induced hepatocarcinoma in a mouse model as a potent genotoxic agent [8, 9]. Initially, rapid killing of hepatocytes was induced by DEN alone. But DEN by itself requires a long time to induce hepatocellular carcinoma but the assistance of tumor promoters like CCl₄ ensures a shorter time span for the development of liver cancer [10]. Hence, this study concerns the application of DEN associated with CCl₄ (Fig. 1b) to induce HCC in male Swiss albino mice model, which is again another potent hepatotoxin [11, 12]. Female mice have been reported to be resistant to HCC; hence, only male mice have been used and analyzed in this study [13]. White albino mice are internationally accepted model which could be extrapolated to human beings. Further, their ease of maintenance, handling, and their high reproduction rate make them particularly suitable models for human-oriented research. Their genome has been sequenced and many genes have human homologs.

The present investigation focused to elucidate the beneficial effect of natural plant-derived β-carboline alkaloid, harmalol, against HCC in the mice model to design a better therapeutic agent worldwide. Earlier, the aqueous and alcoholic extracts of Peganum harmala seeds having β-carboline alkaloid extracts have been reported to show potent antitumor and antiproliferative activity [14]. P. harmala extract caused a significant improvement in liver and kidney function in mice administered methotrexate drug [15]. However, our previous investigations on this naturally occurring indole derivative showed that it induced ROS-mediated, caspase 3- and p53-activated apoptosis against in vitro HepG2 cells [16]. It showed intercalative mode of binding, preferred hetero GC sequence specificity [17], and exhibited RNA binding ability [18]. But, most of the detailed therapeutic indications of harmalol are still a lacuna. Hence, this investigation primarily focused on several liver marker enzymes and gross morphological assessment of liver associated with several histological alterations that lead to HCC has been included in this study. Furthermore, the effective minimum dose of harmalol treatment is also included that finally put a conclusion through mRNA expression by RT-PCR and apoptotic marker proteins by western blot study in addition to the in vivo ROS generation analysis.

**Methods**

**Chemicals and reagents**

Harmalol and CT DNA were purchased from Sigma-Aldrich (St. Louis, MO, USA). The purity of the sample

---

**Fig. 1** A representative figure (top panel) showing the DNA-adduct formation by DEN upon titration with CT DNA. Chemical structure of a (inset) DEN, b CCl₄, and c Harmalol
was confirmed as done earlier [17, 19]. Their concentrations were determined using their molar extinction coefficient value of 19,000 and 6600 M⁻¹ cm⁻¹, respectively, at 371 and 260 nm [17]. DEN (N-nitrosodiethylamine) was also purchased from Sigma-Aldrich (St. Louis, MO, USA) and CCl₄ was purchased from Merck, India. All chemical reagents for phosphate buffer Saline and 10% neutral buffer formalin that were used were of analytical grade.

UV-spectroscopic studies
The absorbance spectral studies between DEN and CT DNA were measured on a Jasco V-630 double beam monochromator spectrophotometer (Jasco International Co. Ltd. Tokyo, Japan) of 1-cm pathlength at 25 ± 0.5 °C

Animal care and experiment
Male Swiss albino mice (Mus musculus) weighing 20–22 g (4–6 weeks old) were purchased from a registered breeder of animals. All mice were bred and maintained under constant conditions at a temperature of 24 ± 1 °C and humidity of 55 ± 5% with 12-h light and 12-h dark cycles. Water and feed were accessible to the mice ad libitum [20]. Animal care (clean cage with sterilized bedding, food, drinking water) and all experimental protocols were performed according to the health criteria of laboratory animals and the study was conducted after obtaining Institutional Animal Ethical Committee clearance under the registration no. 892/GO/Re/S/01/ CPCSEA, dated 20 April 2014–28 April 2019, University of Kalyani. The animals were kept under quarantine for 1 week prior to the experiment. All experimental animals were procured from a registered breeder (address: Shri Sanjay Saha, Proprietor, Saha Enterprise, 386/2 Nilachal Birati, Kolkata 700051, W. Bengal) and they transported the animals in good health (certified by an appointed veterinarian) in the animal house. Animal cage size of 290 × 220 × 140 mm, made of PVC, are generally used accommodating two animals per cage with proper labeling.

The dose for euthanasia was 30 mg/kg of Ketamine-HCl and 3 mg/kg of Xylazine-HCl, intraperitoneally (I.P.) given. Duration of effect was ~ 30 min.

Animal care and experimentation adheres to ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments)

Experimental design
The dose of both carcinogen and harmalol were selected as per the LD₅₀ and acute toxicity of mice maintained under constant laboratory conditions [21]. The calculated LD₅₀ of DEN, CCl₄ and harmalol are 465 mg/kg, 3 ml/kg, and 190 mg/kg body weight, respectively, through I.P. However, the acute toxicity of DEN, CCl₄, and harmalol are 310 mg/kg, 2.2 ml/kg, and 120 mg/kg body weight, respectively.

Figure S1 represents a schematic illustration of in vivo experimental design of induction towards hepatocellular carcinoma and its treatment with harmalol. Experimental male mice were randomly divided into seven groups, each group consisting of five animals and their periodic induction with carcinogen and treatment with harmalol according to Table 1.

- **Group I:** Controls received the vehicle of normal saline (0.2 ml/kg, B.W. I.P.) and made sacrifice after 21st week.
- **Group II:** Received harmalol (10 mg/kg B.W., I.P. per week) for 9 weeks
- **Group III:** Received DEN (24 mg/kg B.W. of I.P.) for first 12 weeks and received the vehicle of normal saline (0.2 ml/kg, B.W. I.P.) for last 9 weeks, and the total accumulation of DEN was (288 mg/kg B.W of I.P.) for 12 weeks
- **Group IV:** Received CCl₄ (0.2 ml/kg B.W.) for the first 4 weeks (total accumulation of 0.8 ml/kg, B.W of I.P)
- **Group V:** Received DEN (24 mg/kg B.W. of I.P.) for first 12 weeks (total accumulation was 288 mg/kg, B.W.) and simultaneously administered CCl₄ (0.2 ml/kg B.W. of I.P.) for 4 weeks (Total accumulation of 0.8 ml/kg, B.W of I.P) and received the vehicle of normal saline (0.2 ml/kg, B.W. of I.P.) for last 9 weeks
- **Group VI (pre-treated):** Received aqueous solution of harmalol of (10 mg/kg B.W of I.P.) for first 9 weeks followed by administration of DEN + CCl₄ up to the 21st week (dose vide supra)
- **Group VII (post-treated):** Mice post-treated with harmalol (10 mg/kg body weight) for 9 weeks after the administration of DEN for 12 weeks (i.e., after administering DEN alone for 12 weeks, the mice were treated with harmalol along with DEN for another 9 weeks) and continued till the end of the experiment.

The carcasses of the sacrificed mice were disposed of by biomedical waste disposal method.

Gross morphological assessment of liver
The mice were weighed periodically and their body weights were recorded. The livers of the respective groups were removed, weighed, and examined for the presence of grossly visible lesions, and morphological changes were observed.

Transmission electron microscopy
Transmission electron microscopy (TEM) was performed using TECNAI 200KV TEM (Fei Electron Optics), 35 mm Photography System from All India Institute of Medical Science, N. Delhi. HepG2 cells were seeded in 100 mm plates at a density of 2 × 10⁶ cell in DMEM cell culture media for overnight and after adherence, cells were treated with harmalol of 7, 14, and 21 μM concentrations (concentrations at GI25, GI50, and GI75, respectively) at 37 °C for 48 h. Cells were trypsinized and then the cultured materials were centrifuged
at 3000 rpm for 4–5 min to discard the supernatant. The pellet was suspended in 0.1 M phosphate buffer (pH 7.4), dispersed, and centrifuged again. The pellet was resuspended and fixed in a mixture of 2% paraformaldehyde and 2.5% glutaraldehyde in buffer for 3–4 h at 4 °C, centrifuged for 10 min at 4 °C and the supernatant were discarded. The samples were finally prepared for observation.

Assessment of liver function by enzyme assay
Blood from seven different groups of mice was collected from the tail-vein after a specific time interval. Serum was obtained by centrifugation at 3000 rpm for 10 min at 4 °C. Biochemical parameters, i.e., ALP [22], lactate dehydrogenase (LDH) assay [23], total bilirubin, AST, and ALT [24] were analyzed according to the reported methods. The kits for ALP, LDH activity, total bilirubin, AST, and ALT were purchased from Span Diagnostic, India.

Determination of ALP
The response of the liver to any form of damage and obstruction is to synthesize more ALP [25–27]. Changes in absorbance are measured kinetically at 405 nm due to yellow color formation and are proportional to ALP activity in the sample [25, 26, 28].

ALP activity (IU/L) = ΔA/minute × Kinetic factor, where ΔA/minute = change in absorbance per minute and Kinetic factor (K) = 2712

Determination of activity of LDH
Increased levels of LDH were also found in case of hepatic diseases [23]. Serum sample of each group (untreated and treated groups) was mixed well. The initial absorbance $A_0$ was measured spectrophotometrically at 340 nm and reading was taken repeatedly after every 1, 2, and 3 min. The mean absorbance change per minute ($\Delta A$/min) was calculated as follows:

$$LDH \text{ activity in U/L for } 25^\circ C/30^\circ C = \frac{\Delta A\text{/min} \times 3333}{8095}$$

Determination of total bilirubin
Red-purple-colored azobilirubin is measured spectrophotometrically at 540 nm and it is proportional to the concentration of the appropriate fraction of bilirubin. The concentration of total bilirubin was calculated in mg/100 ml.

Detection of activity of AST
Serum AST level is elevated in case of liver diseases associated with hepatic necrosis. Serum samples of each group were mixed with working AST reagent and absorbances were taken at 340 nm.

$$AST \text{ activity (IU/L)} = \frac{\Delta A\text{/minute} \times \text{Kinetic factor}}{\text{minute and Kinetic factor (K) = 1768}}$$

Detection of activity of ALT
Serum ALT level is also elevated in case of liver diseases associated with hepatic necrosis. ALT is a more liver-specific enzyme. Serum sample of each group was mixed well with working AST reagent and absorbances were taken and reading was taken at 340 nm.
Detection of hepatocarcinoma indicators
The activity of hepatic DNA in the liver tissue was assayed by methods of Giles and Myres [29] and Burton [30]. The hepatic RNA level was estimated by methods of Almog and Shirey [31] and Blobel and Potter [32]. Hepatic protein was estimated by the method of Lowry et al. [33]. The activity of serum alpha-fetoprotein (AFP) level was also assayed.

Histological studies
Mice from each group were taken and sacrificed after a specific time interval. After draining the blood, liver samples were excised, washed with normal saline (0.9% NaCl), and processed separately for histopathological observation according to Alarami [34]. The hematoxylin and eosin (H&E) stained sections were examined under a light microscope, Leitz (Biomed), and histopathological changes were captured by a Nikon Camera, EOS700D, 18–55 lens.

RT-PCR and western blot analysis
Equal amounts of total RNA, extracted with TRIZOL Reagent (Himedia, Mumbai, India), were reverse transcribed and then subjected to PCR with enzymes and reagents of the reverse transcription system using the technique of PCR system as reported earlier by Sarkar et al. [16]. Sequences of primers used in the study are given in Table S1. G3PDH was used as loading control. PCR kit (Taq Mix Kit), RT-PCR kit, and RNasin were purchased from SRL, Pvt. Ltd. Oligonucleotide primers for caspase3, p53, and G3PDH were purchased from Xcelris Labs Limited.

Total protein content from the liver of the control, harmalol post-treated, and DEN- and CCl4-induced group of mice were extracted and western blot analysis was performed as described by Lee [35]. Tubulin was used as loading control. Anti-active caspase 3 monoclonal primary antibody (17 Kd, anti-mouse, Santa Cruz Biotechnology), tubulin, and anti p53 monoclonal primary antibody (anti-mouse) were purchased from Santa Cruz Biotechnology, and anti-mouse secondary antibody was purchased from Sigma-Aldrich.

In vivo ROS generation and its quantification by FACS
The liver from different groups was collected and a freshly prepared solution of 0.5 mM EDTA and collagenase type I 0.8 mg/ml in DMEM media was added to the section of the liver sac to release the hepatocytes according to Severgnini et al. [36]. The levels of intracellular ROS were assessed by flow cytometry after incubating with DCFH-DA (20 mM) (dichloro fluorescence diacetate) for 30 min at 37 °C.

Statistical analysis
The data obtained were calculated by SPSS 17.0. The values were expressed as mean ± SEM. Statistical analysis was performed by one-way analysis of variance (ANOVA). Values of \( p < 0.05 \) were considered significant.

Results
UV-vis spectral changes
DEN (diethylnitrosamine) is a potent hepatocarcinogenic nitrosamine compound, which is present in several sources. It is the nitrosamine that has the carcinogenic effect [37]. Endogenous nitrosamines can be formed in a similar way from their precursors, nitrates, and nitrates. The binding between DEN and CT DNA was studied by UV-vis absorption titration (Fig. 1). The characteristic UV-vis spectrum of DEN exhibited maxima at 338 nm in the range of 300–410 nm. On titration with CT DNA of varied concentration and DEN of fixed concentration (15 μM), the spectra exhibited a characteristic hypochromic effect of 18% and a bathochromic shift of 4 nm until saturation was reached at nucleotide phosphate/DEN molar ratio (P/D) 4.0. The characteristic hypochromic effect and bathochromic shift indicated a strong intermolecular interaction. But throughout the binding, no isosbestic point was observed that signifies that the interaction was not equilibrium based non-covalent binding.

In vitro cytotoxicity studies of harmalol in HepG2 cell line
Apart from the binding study, the biological importance was further highlighted by in vitro cytotoxic assays to emphasize the apoptotic induction ability of harmalol in liver cancer cell line HepG2. Previously Sarkar et al. [16] had already revealed that harmalol showed cytotoxicity in different human cancer cell lines and out of all, HepG2 cell line showed maximum cytotoxicity with a minimum IC50 value of 14.2 μM. Figure 2a depicts the phase-contrast microscopic images of the control and treated HepG2 cells with different concentrations of harmalol. Furthermore, ultra-morphological study by TEM (Fig. 2b), which is considered the customary to confirm apoptosis, further discovered some early and late
apoptotic features like nucleolus fragmentation, cytoplasmic blebbing, and formation of phagolysosomal complex. ROS generation study was also performed (Fig. 2c) by adding DCFH-DA (25 μM) in control and harmalol-treated HepG2 cells (at IC50 concentration) for 24 h under a fluorescent microscope.

**Light microscopic studies**

Light microscopic images of the intact liver are shown in Fig. 3a–c. Control (Group I) mice showed normal as a reddish-brown wedge-shaped architecture of the liver (Fig. 3a). Macroscopically the liver extracted from group V showed several lesions as multifocal nodular hyperplasia.
and the entire structure was complete whitish-pink in color with blood drained structure. Multifocal and infiltrating types of growth patterns were observed in DEN+CCl4 (Group V)-injected mice liver (Fig. 3b). While harmalol post-treated (group VII) mice liver was also found in near-normal architecture, reddish-brown color, and normal shape and size (Fig. 3c). The results further showed the disappearance of gray-white nodular patches from the surface of the liver after 9 weeks of post-treatment (total accumulation of 90 mg/kg of harmalol). Light microscopic examinations of the liver of the remaining experimental groups have been shown in Figure S2.

**General observation and body and liver weight**

The final body weight and absolute liver weights were also collated in Table 2. All groups were subjected to dying sacrifice after 21 weeks. Final body weights were remarkably decreased in group III with a body weight of 17.3 ± 3.2 g and group V with 13.6 ± 1.6 g body weight as compared with harmalol-treated and control group (division of various groups in details have been shown in the “Experimental design” section). But, the absolute liver weights in the mentioned groups (i.e., groups III, IV, and V) were significantly decreased, though the decrease was more pronounced among group V and it was 0.96 ± 0.9 g (Fig. 3b). Decreased liver weight in these groups was attributed to decreased body weight.

**Assay of liver marker enzymes**

After the study of apparent body and liver weight, blood samples from all seven groups were collected and serum level of alkaline phosphatase (ALP), lactate dehydrogenase (LDH), bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were estimated. Data obtained from the biochemical assays were analyzed and presented in Table 3 which showed the mean serum levels of ALP, LDH, bilirubin, AST, and ALT in all healthy or controlled, harmalol control, different groups of carcinogens induced, and harmalol pre- and post-treated groups of mice, respectively. The parameters were further represented as a bar graph (Fig. 4a–e). The values of all these enzymes were significantly higher ($p < 0.05$) in DEN+CCl4, i.e., group V treated group with 650.85 ± 20 IU/L, 1801.1 ± 60 IU/L, 2.36 ± 0.098 mg/dL, 495.5 ± 18 IU/L, and 477.36 ± 15 IU/L in ALP, LDH, bilirubin, AST, and ALT, respectively. It showed the highest percentage of marker liver enzymes above the normal level.

Furthermore, there was a drop in the hemoglobin level in the hepatocarcinoma-affected mice. Normal hemoglobin was found to be 9.7 mmol/L, whereas in the diseased mice it was 8.4 mmol/L, reflecting acute anemia. In the post-harmalol-treated group, it was reported to be 9.3 mmol/L.

**Alpha-fetoprotein as hepatocarcinoma indicator**

The changes in the level of hepatic DNA, RNA, and normal serum protein level in the liver tissue of control and experimental groups were studied and the quantitative values are presented in Table 4 and Fig. 5a. Mice administered with DEN/CCl4 showed a significant increase in DNA and RNA levels than the control and post-treated groups while the normal serum protein level was significantly low in the group of mice administered with DEN/CCl4 compared to control and post-treated groups. But, the activity of serum alpha-fetoprotein (AFP) level was significantly increased in DEN/CCl4 when compared to

### Table 2  Body and liver weight in Swiss albino mice

| Group no. | Treatment               | No. of Mice | Final weight (g) | 1st week | 7th week | 14th week | 21st week |
|-----------|-------------------------|-------------|-----------------|----------|----------|-----------|-----------|
| I         | Control (untreated)     | 5           | Body            | 25.3 ± 2.1| 25.7 ± 2.3| 26.1 ± 2.2| 26.3 ± 2.1|
|           |                         |             | Liver           | 1.69 ± 0.13| 1.68 ± 0.12| 1.69 ± 0.14| 1.69 ± 0.13|
| II        | Harmalol treated        | 5           | Body            | 25.6 ± 2.3| 26.2 ± 2.1| 26.8 ± 2.4| 25.1 ± 2.3|
|           |                         |             | Liver           | 1.66 ± 0.11| 1.57 ± 0.12| 1.58 ± 0.14| 1.55 ± 0.13|
| III       | CCl4 treated            | 5           | Body            | 25.2 ± 3.1| 22.6 ± 3.1| 19.1 ± 3.4| 17.3 ± 3.2*|
|           |                         |             | Liver           | 1.62 ± 0.28| 1.56 ± 0.22| 1.43 ± 0.32| 1.35 ± 0.36*|
| IV        | DEN treated             | 5           | Body            | 24.5 ± 1.9| 20.2 ± 1.5| 17.5 ± 1.1| 15.6 ± 1.2*|
|           |                         |             | Liver           | 1.50 ± 0.27| 1.41 ± 0.25| 1.33 ± 0.14*| 1.19 ± 0.11*|
| V         | DEN+CCl4 treated        | 5           | Body            | 20.2 ± 2.9| 18.3 ± 3.6| 15.4 ± 2.7| 13.6 ± 1.6*|
|           |                         |             | Liver           | 1.45 ± 0.16| 1.32 ± 0.19| 1.23 ± 0.33*| 0.96 ± 0.9*|
| VI        | Pre-treatment with harmalol | 5     | Body            | 25.5 ± 2.5| 25.3 ± 2.8| 24.6 ± 2.8| 24.1 ± 2.3*|
|           |                         |             | Liver           | 1.59 ± 0.17| 1.57 ± 0.22| 1.56 ± 0.27| 1.49 ± 0.23*|
| VII       | Post-treatment with harmalol | 5     | Body            | 20.6 ± 2.4| 18.2 ± 2.6*| 22.8 ± 2.2*| 24.9 ± 1.8|
|           |                         |             | Liver           | 1.47 ± 0.24| 1.33 ± 0.29*| 1.46 ± 0.25*| 1.66 ± 0.23|

Mice were sampled 21 weeks after the initiation of treatment, and values represented means ± SE

*Significantly different from the control groups ($p < 0.05$)
Table 3 Serum levels of liver enzyme activity\(^a\) * in IU/L (for ALP, LDH, AST, and ALT) and in mg/Dl (for bilirubin)

| Group          | After the 1st week | After the 7th week | After the 14th week | After the 21st week |
|----------------|--------------------|--------------------|--------------------|--------------------|
|                | ALP    | LDH    | Bilirubin | AST    | ALP    | LDH    | Bilirubin | AST    | ALP    | LDH    | Bilirubin | AST    | ALP    | LDH    | Bilirubin | AST    |
| I control      | 72.15 ± 0.48 ± 55.6 ± 43.2 ± | 73.9 ± 0.47 ± 56.8 ± 43.9 ± | 73.2 ± 0.48 ± 55.9 ± 43.1 ± | 73.76 ± 0.47 ± 55.9 ± 43.8 ± |
|                | 2 ± 6  | 4 ± 6  | 2 ± 6     | 2 ± 6  | 2 ± 6  | 2 ± 6  | 2 ± 6     | 2 ± 6  | 2 ± 6  | 2 ± 6  | 2 ± 6     | 2 ± 6  | 2 ± 6  | 2 ± 6  | 2 ± 6     | 2 ± 6  |
| II harmolol    | 73.6 ± 0.5 ± 60.9 ± 52.6 ± | 73.1 ± 0.51 ± 73.8 ± 62.3 ± | 72.8 ± 0.52 ± 84.9 ± 69.7 ± | 70.5 ± 0.52 ± 102.5 ± 84.9 ± |
|                | 3 ± 6  | 3 ± 6  | 3 ± 6     | 3 ± 6  | 3 ± 6  | 3 ± 6  | 3 ± 6     | 3 ± 6  | 3 ± 6  | 3 ± 6  | 3 ± 6     | 3 ± 6  | 3 ± 6  | 3 ± 6  | 3 ± 6     | 3 ± 6  |
| III CCl\(_4\)  | 115.73 ± 0.52 ± 69.3 ± 53.6 ± | 166.35 ± 0.77 ± 122.5 ± 131.3 ± | 203.14 ± 0.8 ± 181.3 ± 215.5 ± | 257.64 ± 0.8 ± 265.2 ± 318.24 ± |
|                | 4 ± 7  | 4 ± 7  | 4 ± 7     | 4 ± 7  | 4 ± 7  | 4 ± 7  | 4 ± 7     | 4 ± 7  | 4 ± 7  | 4 ± 7  | 4 ± 7     | 4 ± 7  | 4 ± 7  | 4 ± 7  | 4 ± 7     | 4 ± 7  |
| IV DEN         | 136.3 ± 0.82 ± 75.4 ± 69.2 ± | 310.5 ± 1.02 ± 157.3 ± 137.2 ± | 401.3 ± 1.14 ± 225.7 ± 230.2 ± | 542.4 ± 1.16 ± 318.3 ± 380.12 ± |
|                | 5 ± 8  | 5 ± 8  | 5 ± 8     | 5 ± 8  | 5 ± 8  | 5 ± 8  | 5 ± 8     | 5 ± 8  | 5 ± 8  | 5 ± 8  | 5 ± 8     | 5 ± 8  | 5 ± 8  | 5 ± 8  | 5 ± 8     | 5 ± 8  |
| V               | 205.2 ± 0.97 ± 137.2 ± 103.2 ± | 320.1 ± 1.55 ± 20.5 ± 22.3 ± | 457.35 ± 1.92 ± 350.2 ± 365.5 ± | 650.85 ± 2.36 ± 495.5 ± 477.36 ± |
|                | 5 ± 9  | 5 ± 9  | 5 ± 9     | 5 ± 9  | 5 ± 9  | 5 ± 9  | 5 ± 9     | 5 ± 9  | 5 ± 9  | 5 ± 9  | 5 ± 9     | 5 ± 9  | 5 ± 9  | 5 ± 9  | 5 ± 9     | 5 ± 9  |
| VI pre-treated | 73.2 ± 0.51 ± 69.2 ± 56.5 ± | 76.7 ± 0.53 ± 74.5 ± 65.3 ± | 82.2 ± 0.59 ± 104.2 ± 67.2 ± | 83.68 ± 0.64 ± 113.16 ± 84.5 ± |
|                | 2 ± 6  | 2 ± 6  | 2 ± 6     | 2 ± 6  | 2 ± 6  | 2 ± 6  | 2 ± 6     | 2 ± 6  | 2 ± 6  | 2 ± 6  | 2 ± 6     | 2 ± 6  | 2 ± 6  | 2 ± 6  | 2 ± 6     | 2 ± 6  |
| VII post-treated | 207.7 ± 0.95 ± 136.8 ± 105.3 ± | 318.3 ± 1.59 ± 222.7 ± 215.5 ± | 207.7 ± 0.95 ± 113.62 ± 148.7 ± | 79.552 ± 0.42 ± 74.76 ± 58.6 ± |
|                | 4 ± 9  | 4 ± 9  | 4 ± 9     | 4 ± 9  | 4 ± 9  | 4 ± 9  | 4 ± 9     | 4 ± 9  | 4 ± 9  | 4 ± 9  | 4 ± 9     | 4 ± 9  | 4 ± 9  | 4 ± 9  | 4 ± 9     | 4 ± 9  |

\(\text{Values represented means ± SD}\)

\(\text{*Significantly different from the control groups (p < 0.05)}\)
Fig. 4 Bar graph representation showing the effect of carcinogen (DEN+ CCl₄) and harmalol treatment on experimental mice by measuring the serum level of liver functional enzymes. a ALP, b LDH, c bilirubin, d AST, and e ALT after different time period. Control, harmalol-treated (total 80 mg/kg B.W.), CCl₄-treated, DEN-treated, DEN+CCl₄-treated, pre-treatment (Pre-T) with harmalol (total 80 mg/kg B.W.) and post-treatment (Post-T) with harmalol (total 80 mg/kg B.W.) are presented here. Data are presented as mean ± SE, *P < 0.05 compared with the control group; #P < 0.05 compared with the DEN+CCl₄-treated group.

Table 4 Quantitative values of different hepatic marker viz. DNA, RNA, protein, and AFP levels* after the 21st week of exposure of harmalol and carcinogens

| Groups | DNA     | RNA    | Normal serum protein | AFP level in serum |
|--------|---------|--------|----------------------|--------------------|
| I      | 0.7 ± 0.1 | 0.9 ± 0.08 | 13.5 ± 0.1 | 0.30 ± 0.02 |
| II     | 0.75 ± 0.2 | 0.92 ± 0.009 | 12.9 ± 0.2 | 0.34 ± 0.03 |
| III    | 2.1 ± 0.6 | 2.6 ± 0.4 | 8.4 ± 0.5 | 0.80 ± 0.05 |
| IV     | 1.9 ± 0.4 | 2.2 ± 0.3 | 9.2 ± 0.5 | 0.79 ± 0.04 |
| V      | 2.6 ± 0.7 | 2.8 ± 0.6 | 7.6 ± 0.8 | 0.83 ± 0.07 |
| VI     | 1.6 ± 0.4 | 1.8 ± 0.2 | 10.2 ± 0.3 | 0.55 ± 0.03 |
| VII    | 1.2 ± 0.3 | 1.6 ± 0.1 | 11.8 ± 0.2 | 0.42 ± 0.02 |

*Values represented means ± SD

*Significantly different from the control groups (P < 0.05)
the normal group (Fig. 5b). A significant reduction in serum AFP level was observed in the treatment group (harmalol post-treated) when compared with DEN/CCl4 group.

**Histological study**

Apart from the above study, a histological study was performed under light microscope using hematoxylin and eosin stain. Histology signifies the microscopic examination of tissue in order to study the manifestations of the specific disease. Specifically, in clinical medicine, histology, along with its pathological outcome, refers to the examination of a biopsy or surgical specimen, after the specimen has been processed and histological sections have been placed onto glass slides. In the presence of combined carcinogen, DEN+CCl4 several characteristics of liver necrosis and HCC were found in experimental system after 12 weeks of injection and were presented in Fig. 6 elaborately. Toxic chemicals like several nitrosamine compounds, used as common food additives, could
induce HCC and could cause zonal necrosis of the liver [38, 39]. Here, DEN+ CCl₄ induced two types of zonal necrosis. Figure 6a shows centrilobular necrosis involving necrosis in hepatocytes around the central vein, while Fig. 6b shows fibrolamellar carcinoma where oncocytes formed cords (A1) and nests (A2) which were separated by bands of fibrous stroma (A3). Figure 6c (B1, B2) showed peripheral or periportal necrosis involving necrosis in parenchyma closest to the arterial and portal blood supply while (C1) and (C2) showed pyknotic condition in the nuclei of hepatic cells. Figure 6d portrayed trabecular or sinusoidal patterns which were actually made up of 2–8-cell-wide layers of tumor cells separated by vascular spaces or sinusoids which are lined by endothelium. Figure 6e (D1, D2) showed different changes in liver tissues like nodule formation and fibrosis or cirrhosis, respectively. Figure 6f (H&E stained liver sections are photographed at × 100 magnification).

**Fig. 6** Hematoxylin and eosin (H&E) stained liver sections of DEN+CCl₄-induced mice (group V). a Centrilobular necrosis. b Fibrolamellar carcinoma liver where (A1) oncocytes, (A2) cord patterns, and nest formation which were separated by bands of (A3) fibrous stroma. c Peripheral/ periportal necrosis shown by (B1) and (B2), and (C1) and (C2) (pyknotic condition in the nuclei of hepatic cells). d Trabecular or sinusoidal patterns which are made up of 2–8-cell-wide layers of tumor cells separated by vascular spaces or sinusoids which are lined by endothelium. e (D1) and (D2) Different changes in liver tissues like nodule formation and fibrosis or cirrhosis, respectively. f Large eosinophilic AHF. g Small basophilic AHF. h Vacuolated cell AHF. H&E stained liver sections are photographed at × 100 magnification.

Figure 7 further summarized the results of the histological examinations of untreated, carcinogen-induced, harmalol pre- and post-treated mice liver elaborately. Several characteristics of HCC and necrosis described above were identified in the carcinogen-induced group and HCC was found to be developed in the DEN+CCl₄-treated group (group V) after the 12th week. HCC was identified in the CCl₄-treated group (group IV) also. In all DEN-treated groups (group III), large eosinophilic and small basophilic AHF was identified. AHF condition increased in a dose-dependent manner and was statistically significant as compared with harmalol-treated and controlled values. Eosinophilic AHF was positively correlated to dose, but only those identified in group V were statistically significant. DEN+CCl₄ treatment led to a severe pyknotic condition of hepatic cells nuclei, vesiculation in the cytoplasm of the cells, sign of damage in the wall of central veins, hemorrhage, necrotic foci, degeneration, and hypertrophy in some of the hepatic cells. While the DEN-treated group showed a widening of some of the hepatic sinusoids, histology of CCl₄-treated groups showed different changes in liver tissues like...
fibrosis (cirrhosis) and mononuclear polymorphic infiltration besides widening in some of the hepatic sinusoids, pyknotic, and vesiculation of hepatic cells. Thus, it can be summarized from the histopathological examination of mice in group III (DEN-treated mice) and group IV (CCl₄ treated mice) that histopathological deformities were far more prominent in group V, i.e., DEN+CCl₄-treated group. While control group animals revealed normal architecture and animals pre-treated and post-treated with harmalol (90 mg/kg B.W.) showed fewer neoplastic cells with the near-normal architecture of a very compact hexagonal or pyramidal structure with a very prominent central vein.

Effect of harmalol on p53 and caspase 3 expressions

Hepatoprotective action of harmalol was further confirmed by RT-PCR data revealing that unlike in the control group of mice, harmalol post-treatment resulted in activation of caspase 3 and increased expression of p53 (Fig. 8a). The expression of caspase-3, p53, and cytochrome C that favored apoptosis were up-regulated in a harmalol post-treated group (Fig. 8b). Figure 8b further exhibited the cleaved form of caspase-3, i.e., 17/19 kd. Together, the present results showed that harmalol induces apoptosis by potentially targeting the cleavage of pro-caspase-3 (34 kd) into active enzyme and both forms of caspase-3 expression by western blot analysis, which are given with its quantitative presentation. Quantification of each marker is been represented by bar graphs. Evidence suggested that the p53 tumor suppressor gene is involved in cell cycle regulation, DNA repair, and programmed cell death, and it further led to caspase activation [40, 41].

In vivo ROS detection

The result was further complemented with in vivo ROS-dependent cytotoxicity. ROS generation, induced by various anti-cancer agents [42–44], plays a key role in apoptosis. ROS levels were found to be elevated in the harmalol post-treated group. The mean fluorescent intensity changed (Table 5) from 21.3 ± 0.9 (control) to
28.6 ± 0.8, 71.4 ± 0.8, and 85.4 ± 0.7 in harmalol post-treated, DEN, and DEN+CCl₄-induced group, respectively (Fig. 9). ROS intensity increased nearly 4-folds relative to the control.

**Discussion**

Ability to induce apoptosis in cancer cells is an established hallmark feature of any drug with a good anti-cancer potential [45]. Hence, the study highlighted the apoptotic induction ability of harmalol in an in vivo model to quantify the efficacy of the drug molecule inhibiting carcinogens inducing hepatocellular carcinoma (HCC). In vivo study was performed in seven groups of male Swiss albino mice administered with both DEN and CCl₄. DEN by itself requires a long time to induce hepatocarcinoma, but the assistance of tumor promoters like CCl₄ ensures a shorter time span for the development of liver cancer [10]. CCl₄ enhanced hepatocyte proliferation through indirect mechanisms. Essentially, their primary effect is cytotoxicity that eventually triggers compensatory proliferation [10, 46].

DEN+CCl₄ application leads to dilatation of central veins and pooling of blood in the sinusoids towards the center of the liver lobule with hemorrhage in hepatic tissues, centrilobular and peripheral necrosis, fibrolamellar carcinoma, pyknotic in the nuclei of hepatic cells, cancer potential [45]. Hence, the study highlighted the apoptotic induction ability of harmalol in an in vivo model to quantify the efficacy of the drug molecule inhibiting carcinogens inducing hepatocellular carcinoma (HCC). In vivo study was performed in seven groups of male Swiss albino mice administered with both DEN and CCl₄. DEN by itself requires a long time to induce hepatocarcinoma, but the assistance of tumor promoters like CCl₄ ensures a shorter time span for the development of liver cancer [10]. CCl₄ enhanced hepatocyte proliferation through indirect mechanisms. Essentially, their primary effect is cytotoxicity that eventually triggers compensatory proliferation [10, 46].

DEN+CCl₄ application leads to dilatation of central veins and pooling of blood in the sinusoids towards the center of the liver lobule with hemorrhage in hepatic tissues, centrilobular and peripheral necrosis, fibrolamellar carcinoma, pyknotic in the nuclei of hepatic cells, cancer potential [45]. Hence, the study highlighted the apoptotic induction ability of harmalol in an in vivo model to quantify the efficacy of the drug molecule inhibiting carcinogens inducing hepatocellular carcinoma (HCC). In vivo study was performed in seven groups of male Swiss albino mice administered with both DEN and CCl₄. DEN by itself requires a long time to induce hepatocarcinoma, but the assistance of tumor promoters like CCl₄ ensures a shorter time span for the development of liver cancer [10]. CCl₄ enhanced hepatocyte proliferation through indirect mechanisms. Essentially, their primary effect is cytotoxicity that eventually triggers compensatory proliferation [10, 46].

**Fig. 8** a RT-PCR analysis conducted with a cytosolic fraction of caspase 3 and p53 activation G3PDH was used as an internal control for normalization of equal loading. b Western blot analysis of caspase 3, p53, and cytochrome c from whole protein extracted from the liver of the control, DEN+CCl₄-induced, and post-treatment with harmalol of HCC-induced mice. Tubulin was used as loading control. Bar graphs represent the quantification of each marker.

### Table 5

Comparison between quantitative assay of ROS generation induced by harmine by DCFH-DA in HeLa cell lines through Flow cytometric analysis

| Percent ROS a, b, * | Control | Harmalol post-treated | DEN | DEN+CCl₄ |
|---------------------|--------|-----------------------|-----|----------|
|                     | 21.3 ± 0.9 | 28.6 ± 0.8 | 71.4 ± 0.8 | 85.4 ± 0.7 |

*aAverage of three individual experiments at the same conditions

*bValues represented means ±SD

*Significantly different from the control groups (p < 0.05)
to the leakage from the bile canaliculi into hepatic which alkaline phosphatase reaches the circulation due to detect hepatic dysfunction. The mechanism by which the level of ALP in serum may be a sign of liver damage. ALP, an enzyme, is homogenously distributed mainly in the liver, kidney, and bone tissues, a high level of ALP in serum is a sign of liver damage [53]. However, increased activities of these enzymes in serum are found in the cytoplasm and mitochondria of liver cells in high concentrations but low in blood [53]. How-ver, increased activities of these enzymes in serum are due to increased membrane permeability and leakage into the blood circulation when hepatocytes are injured [54], which is the sign of acute necrosis of liver cells. Increased LDH reflected the formation of tumors in the liver. While ALP, an enzyme, is homogenously distributed mainly in the liver, kidney, and bone tissues, a high level of ALP in serum may be a sign of liver damage. Among all liver function tests, ALP is a helpful screening tool to detect hepatic dysfunction. The mechanism by which ALP has been noted to be an HCC prognostic factor in general. The probable overall clinical steps with the outcome have been postulated schematically in Fig. 10.

The activity of hepatic tissue was further studied by estimation of DNA, RNA, normal serum protein, and cancer biomarker alpha-fetoprotein [57]. Earlier, it was proved by investigators that there is a significant elevation of DNA and RNA levels and a decrease in normal serum protein in cancer cells in response to a carcinogen like DEN+CCl_4 [58–60]. In the present study, harmalol-treated animals showed a significant decrease in DNA and RNA level and restoration of normal serum protein when compared to DEN+CCl_4 group further validating the anti-cancer property of the alkaloid. This effect was probably accompanied by cell cycle arrest which was previously reported by the authors in in vitro HepG2 cells by harmalol [16]. However, an elevated level of alpha-fetoprotein AFP, which is a common diagnostic marker, in the serum has been well documented in HCC and germ cell cancers [60]. It was revealed that elevated level of AFP is observed in the adult animals which are exposed to hepatocarcinogens [60]. There are several reports which show that AFP plays a key role in the regulation of tumor growth and cell differentiation and can stimulate the proliferation of human hepatoma cells possibly through the AFP receptors [61–63]. A significant rise in AFP level observed in DEN+CCl_4 group indicates the presence of HCC in mice model. Harmalol post-treated group significantly reduced the rise in AFP level when compared with the DEN+CCl_4 group. This reduction in the treatment group of AFP to a near-normal level may be due to inhibitory effect which confirms the chemopreventive therapeutic action of the alkaloid.

Furthermore, an increase in ROS generation or oxidative stress is an important marker of cancer, and in this study, the ROS intensity has been found to increase nearly 4-folds relative to control in the DEN+CCl_4 group. ROS actually creates disruptions in redox balance. Several studies revealed that p53 has an important role in glucose metabolism and redox regulation. Lu et al. had very elaborately showed the mechanistic insights into the relationship between ROS, tumor suppressors, and oncogenes in p53 mouse models. Increased expression of p53 decreased ROS levels by inhibiting glycolysis and promoting NADPH generation [64].

The balance between cell proliferation and apoptosis is essential for the development and structure-function maintenance of normal organs [65]. The occurrence of cancer is supposedly due to the repression of the normal apoptotic process, which caused the imbalance between cell proliferation and apoptosis [66, 67]. In fact, apoptosis constitutes an
innate tissue defense against carcinogens by preventing the survival of genetically damaged cells. As a result, inhibition of apoptosis has been elucidated as the prevailing mechanism of liver tumor promotion in many rodent studies [68, 69]. This study has highlighted that it is through mitochondrial cytochrome c release that induces p53 by caspase 3 activation via the intrinsic apoptotic pathway [68, 69] which is considered one of the characteristic features of any anti-cancer drug.

**Conclusion**

The present findings clearly demonstrate the chemopreventive, dose-dependent activity of natural alkaloid, harmalol, against diethylnitrosamine (DEN) promoted by carbon tetrachloride (CCl4)-induced hepatocarcinogenesis (HCC) in mice model based on histological study, enzyme assay, and expression of several molecular markers. It has been found that post-treatment of harmalol (10 mg/kg B.W., I.P., per week) for 9 weeks markedly decreased the number of liver tumor nodules, lowered the formation of peripheral and centrilobular necrosis, and helped to regenerate the parenchymal cells in the liver, protecting membrane integrity and decreasing enzyme leakage thereby maintaining the normal histological architect of the liver. It further induces ROS-dependent apoptosis through mitochondrial cytochrome C release that induces p53 by caspase 3 activation. The study also highlighted that action of harmalol is mostly therapeutic rather than prophylactic. So post-treatment with harmalol would be far better than pre-treatment.

The ultimate understanding of these investigations will eventually help to develop more effective chemotherapeutic drugs from the natural product with enhanced efficacy and lower toxicity that can be targeted effectively to cancer-affected specific organ for better therapeutic applications.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s43094-020-00045-x.

**Additional file 1: Figure S1.** Diagrammatic representation of in vivo experimental design of hepatocellular carcinoma HCC induction and its treatment with harmalol in Mus musculus. **Figure S2.** Photographic images of gross liver of different groups of experimental mice. A. Harmalol control for 90 mg/kg b.w, B. DEN (288mg/kg B.W.) for 9 weeks C. CCl4 (0.8 ml/kg b.w) for 4 weeks. D. DEN+CCl4 (after 1st week), E. DEN+CCl4 (after 7th weeks), F. After 14th week of CCl4+DEN, G. Harmalol pre-treated mice liver.

**Abbreviations**

DEN: Diethylnitrosamine; HCC: Hepatocellular carcinoma; AFP: Alpha-fetoprotein; AHF: Altered hepatocellular foci; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase;
CYP2E1: Cytochrome P450 2E1; DCFH-DA: Dichloro fluorescence diacetate; H&E: Hematoxylin and eosin; LDH: Lactate dehydrogenase; ROS: Reactive oxygen species

Acknowledgements
The authors are thankful to PRG University of Kalyani, 2020-21, and Animal Ethical Committee, University of Kalyani, and are grateful to Dr. Partho Pratim Chakraborty, Principal Scientist, ICAR-CIFA, Field Station Kalyani, for providing the light microscopic facility.

Authors’ contributions
SS did the in vivo experiments, conducted the biological assays, and analyzed the data; PB and TG have equal contributions and assisted in the experiments; and KB designed the research and analyzed, compiled, and reviewed the data and wrote the manuscript. The authors read and approved the final manuscript.

Funding
SS is supported by DST-SERB-NPDF (file no. PDF/2017/000398), 2018-20, and KB is indebted to DST-RBRF, 2017-19 (DST/INT/RUS/RBRF/P-254), and the Council of Scientific and Industrial Research (CSIR), Government of India for the financial support (Ref. no. 37 (15381/12/EMR-II). PB is supported by 1 grant from the University of Kalyani. TG is supported by a grant from UGC, Govt. of India.

Availability of data and materials
All data have been included in the text and supplementary file.

Ethics approval and consent to participate
Animal care and all experimental protocols were performed according to the health criteria of laboratory animals and the study was conducted after obtaining Institutional Animal Ethical Committee clearance under the registration no. 983/GO/Re/S/01/CPCSEA, dated 20 April 2014–28 April 2019, University of Kalyani. The animals were kept under quarantine for 1 week prior to experiment. All co-authors and corresponding author have their consent to participate.

Consent for publication
All co-authors and corresponding author have their consent for publication in this journal and authors have acknowledged their respective funding agencies.

Competing interests
No competing financial interests exist. The authors declare no conflict of interest.

The work embodied in this manuscript has not been published previously or is under consideration for publication in any other journal.

Author details
1Department of Zoology, University of Kalyani, Nadia, West Bengal 741235, India. 2Present Address: Division of Molecular Medicine, Bose Institute, Kolkata 700054, India.

Received: 16 February 2020 Accepted: 10 June 2020
Published online: 01 July 2020

References
1. Tsukuma H, Tanaka H, Wakko A, Oshima A (2005) Liver cancer and its prevention. Asian Pac J Cancer Prev 6:244–250 https://www.ncbi.nlm.nih.gov/pubmed/16235981
2. Karin M, Dhar D (2016) Liver carcinogenesis: from naughty chemicals to soothing fat and the surprising role of NRF2. Cancerogenesis 37: 541–546 https://doi.org/10.1093/carcin/bgw060
3. Farber E (1984) The multistep nature of cancer development. Cancer Res 44: 4217–4223 https://www.ncbi.nlm.nih.gov/pubmed/6467183.
4. Bartsch H, Hietanen E, Malaville C (1989) Carcinogenic nitrosamines: free radical aspects of their action. Free Radic Biol Med 7637–644. https://doi.org/10.1016/0891-5849(89)90144-5 https://www.ncbi.nlm.nih.gov/pubmed/2695407
5. Farber JL, Gerson RJ (1984) Mechanisms of cell injury with hepatotoxic chemicals. Pharmacol Rev 36:715–755 https://www.ncbi.nlm.nih.gov/pubmed/6382357
6. Tomatis L, Agthe C, Barths H, Huff J, Montesano R, Saracci R, Walker E, Wilbourn J (1978) Evaluation of the carcinogenicity of chemicals: a review of the Monograph Program of the International Agency for Research on Cancer (1971 to 1977). Cancer Res 38:877 https://cancerres.aacrjournals.org/content/38/4/877
7. Bosnir J, Smit Z, Puntaric D, Horvat T, Klaric M, Simic S, Zoric I (2003) Presence of N-nitrosamines in canned liver patty. Department of Health Ecology, Public Health Institute, Zagreb, Croatia. Coll Antropol 27:67–79 https://www.ncbi.nlm.nih.gov/pubmed/12959894
8. Chuang SE, Kuo MU, Hsu CH, Chen OL, Lin JK, Lai GM, Hsieh CY, Cheng AL (2000) Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatic carcinogenesis. Carcinogenesis 21:331–335 https://www.ncbi.nlm.nih.gov/pubmed/10657978
9. Rajewsky MF, Dauber W, Frankenberg H (1966) Liver carcinogenesis by diethylnitrosamine in the rat. Science 152:828–9 https://www.ncbi.nlm.nih.gov/pubmed/5910014
10. Sakurai T, Maeda S, Chang L, Karin M (2006) Loss of hepatic NF-kappaB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A 103:10544–10551 https://doi.org/10.1073/pnas.0603499103
11. Weisburger JH (1977) Carcinogenicity studies on halogenated hydrocarbons. Environ Health Perspect 21:7–16 https://dx.doi.org/10.1289/ehp.77217
12. Yoksha H, Usuda H, Nakamura T, Nonogaki T, Onosaka S (2016) Carbon tetracloride-induced nephrotoxicity in mice is prevented by pretreatment with zinc sulfate. Biol Pharm Bull 39:1042–1046
13. Nakatani T, Roy G, Fujimoto N, Atahara T, Ito A (2001) Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprolol. Jpn J Cancer Res 92:249–256 https://www.ncbi.nlm.nih.gov/pubmed/11267934
14. Lamchouri F, Settaf A, Cherka Y, Zemzami M, Javidi B, Atif N, Hassar M (1999) Antitumour principles from Peganum harmala seeds. Therapie 54:753–758 https://www.ncbi.nlm.nih.gov/pubmed/10709452
15. Diwan SY (2003) Effect of Peganum harmala methanolic extract on liver and kidney of mice administered MTX drug. J Al-Nahrain University 16:161–166 https://pdfs.semanticscholar.org/9600/20fe57597508731fd2053a42d816bb02833d
16. Sarkar S, Bhattacharjee P, Bhadra K (2016) DNA binding and apoptotic induction ability of harmal in HepG2. Biophysical and biochemical approaches. Chem Biol Interact 258:142–152 https://doi.org/10.1016/j.cbi.201608024
17. Sarkar S, Pandya P, Bhadra K (2014) Sequence specific binding of beta carboline alkaloid harmalol with deoxyribonucleotides: binding heterogeneity, conformational, thermodynamic and cytotoxic aspects. PLoS One 9:1–14 https://doi.org/10.1371/journal.pone.0108022
18. Bhattacharjee P, Sarkar S, Pandya P, Bhadra K (2016) Targeting different RNA motifs by beta carbolinealkaloid, harmalol: a comparative photophysical, calorimetric and molecular docking approach. J Biomol Struct Dyn 34:2722–2740 https://www.ncbi.nlm.nih.gov/pubmed/26629671
19. Sarkar S, Bhadra K (2014) Binding of alkaloid harmalol to DNA: photophysical and calorimetric approach. J Photochem Photobiol B Biol 130:272–280 https://www.ncbi.nlm.nih.gov/pubmed/24368411
20. Hua S, Linglehong Y, Huolling W, Gengtao L (2012) A novel antihepatitis drug, bicyclol, prevents liver carcinogenesis in diethylnitrosamine-initiated and phenobarbital-promoted mice tumor model. J Biomed Biotechnol. DOI: 584728 119, doi:10.1155/2012/584728, https://doi.org/10.1155/2012/584728
21. Velasco-Loyden G, Pérez-Martínez L, Vidrio-Gómez S, Isael Pérez-Carreón J, Chagoya de Sánchez V (2017) Cancer chemoprevention by an adnosine derivative in a model of cirrhosis-hepatocellular carcinoma induced by diethylnitrosamine in rats. Tumor Biol 1–12.
22. Kind PRH, King EJ (1954) Estimation of plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine. J Clin Pathol 7: 322–326 https://doi.org/10.1136/jcp.7.4.322
23. Gubaidullin PG, Wroblewski L (1958) Colorimetric measurement of lactic dehydrogenase activity of body fluids. Am J Clin Pathol 30:234–236 https://doi.org/10.1093/ajcp/30.3.234
24. Retman S, Frankel S (1957) A colorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. Am J Clin Pathol 28:65–63 https://doi.org/10.1093/ajcp/28.1.156
25. Moss DW, Henderson AK (1994) Clinical enzymology. In: Burton CA, Ashwood ER (eds) Teitz textbook of clinical chemistry, 3rd ed. W.B. Saunders, Philadelphia

26. Wengler WC, Lott JA, Kaplan LA, Pesce AJ (1994) Enzymes, In Clinical chemistry: Theory, Analysis and Co-relation. Mosby CV, Toronto

27. Kaplan JR, Manuck SB, Clarkson TB, Lusso FM, Taub DM, Miller EW (1983) Social stress and atherosclerosis in normocolesterolemic monkeys. Science 220:733–735. https://doi.org/10.1126/science.6836311

28. Tietz NW, Rinker AD, Shaw LM (1983) IFCC methods for the measurement of catalytic concentration of enzymes. Part 5. IFCC method for alkaline phosphatase (orthophosphoric-monoester phosphohydrolase, alkaline optimum, EC 3.1.3.1). IFCC Document Stage 2, Draft 1, 1983-03 with a view to an IFCC Recommendation. J Clin Chem Clin Biochem 21:731–748

29. Giles KW, Myres A (1965) An improved diphenylamine method for the determination of RNA. Anal Biochem 91:130–137 https://doi.org/10.1016/0003-2697(81)90283-0

30. Burton K (1956) A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62:315–323 https://doi.org/10.1042/bj0620315 https://dx.doi.org/10.1042/bj0620315

31. Alomg R, Shirey TL (1978) A modified occinol test for the specific determination of RNA. Anal Biochem 91:130–137 https://doi.org/10.1016/0003-2697(81)90283-0

32. Blogeb G, Potter VR (1968) Distribution of radioactivity between the acid-soluble pool and the pools of RNA in the nuclear, nonsedimentable and ribosome fractions of rat liver after a single injection of labeled orotic acid. Biochim Biophys Acta 166:48–57 https://doi.org/10.1016/0005-2788(68)90489-9

33. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407713

34. Alami AMI (2015) Histopathological changes in the liver and kidney of albino mice on exposure to insecticide, dimethoate. Int J Curr Microbiol App Sci 4:287–300 https://www.ijcmas.com/vol-4-7/Alami.%20A.M.%20I%20Alami.pdf

35. Lee C (2007) Protein extraction from mammalian tissues. Methods Mol Biol 362:385–389 https://doi.org/10.1007/978-1-59745-257-1_29

36. Severignini M, Sherman J, Sehgal A, Jayaprakash NK, Aubin J, Wang G, Zhang L, Peng CG, Yucius K, Butler J, Fitzgerald K (2012) A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor based assay development. Cytotechnology 64:187–203 https://doi.org/10.1007/s10616-012-9336-3

37. Reh BD, Fajen JM (1996) A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 315:215–223 https://doi.org/10.1042/bj0315215

38. Russan T, Siddiqui HH, Fareed S, Vijayakumar M, Rao CV (2012) Evaluation of diethylnitrosamine-induced and phenobarbital-promoted hepatocellular carcinoma in rats: Possible chemoprevention by blueberries. Afr J Biomed Res 25:242–250 https://dx.doi.org/10.4314/ajbr.v25i2.1

39. Mohan H (2010) Text book of pathology, 6th ed., Jaypee Brothers Medical Publishers (P)Ltd.

40. Das J, Das S, Samadder A, Khuda-Bukhsh AR (2013) Cytotoxicity and apoptotic signaling cascade induced by chelidonine-loaded PLGA nanoparticles in HepG2 cells in vitro and bioavailability of nano-chelidonine in mice in vivo. Toxicol Lett 222:10–22 https://doi.org/10.1016/j.toxlet.2013.07.006

41. Yamasaki H, Oda Y, Funae Y (1992) Participation of rat liver cytochrome P450 2EI in the activation of N-nitrosodimethylamine and N-nitrosodimethylamine to products genotoxic in an acrylamideformaldehyde-overexpressing Salmonella typhimurium strain (NM2009). Carcinogenesis 13: 979–985 https://doi.org/10.1093/carcin/13.6.979

42. Kujawska M (2009) Protective effect of red beetroot against carbon tetrachloride- and N-nitrosodimethylamine-induced oxidative stress in rats. J Agric Food Chem 57:2570–2575 https://doi.org/10.1021/jf083315d

43. Reda A, Koren R (2003) The role of reactive oxygen species in the anticancer activity of vitamin D. Vitamin d analogs in cancer prevention and aherapy, 164, pp. 357-367, Editors Reichrath J, Tilgen W, Friedrich M, doi http://dx.doi.org/10.1007/978-3-642-55580-0_26

44. Paul A, Das S, Das J, Samadder A, Khuda-Bukhsh AR (2013) Cytotoxicity and apoptotic signaling cascade induced by chelidonine-loaded PLGA nanoparticles in HepG2 cells in vitro and bioavailability of nano-chelidonine in mice in vivo. Toxicol Lett 222:10–22 https://doi.org/10.1016/j.toxlet.2013.07.006

45. Sarkar et al. Future Journal of Pharmaceutical Sciences (2020) 6:29
67. Bursch W, Grasl-Kraupp B, Wastl U, Hufnagl K, Chabicovsky M, Taper H, Schulte-Hermann R (2004) Role of apoptosis for mouse liver growth regulation and tumor promotion: comparative analysis of mice with high (C3H/He) and low (C57Bl/6J) cancer susceptibility. Toxicol Lett 149:25–35. https://doi.org/10.1016/j.toxlet.2003.12.018

68. Li Y, Chen L, Chan TH, Liu M, Kong XL, Qiu JL, Li Y, Yuan YF, Guan XY (2013) SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice. Gastroenterology 144:179–191. https://doi.org/10.1053/j.gastro.2012.09.042

69. Schuler M, Wetzel EB, Goldstein JC, Fitzgerald P, Green DR (2000) p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J Biol Chem 275:7337–7342. https://doi.org/10.1074/jbc.275.10.7337

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.